Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis
| Autor: | Isabella Panaccione, Luigi Dattoli, Maria Pepe, Lorenzo Moccia, Luigi Janiri, Roger S. McIntyre, Marzia Molinaro, Gabriele Sani, Marco Di Nicola |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Hamilton Anxiety Rating Scale Population Alcohol use disorder Double-Blind Method Internal medicine mental disorders medicine Humans education Retrospective Studies Vortioxetine Depressive Disorder Major education.field_of_study business.industry medicine.disease Antidepressive Agents Alcoholism Psychiatry and Mental health Treatment Outcome Mood Digit symbol substitution test Quality of Life Major depressive disorder Anxiety Neurology (clinical) medicine.symptom business |
| Zdroj: | CNS Spectrums. 27:73-81 |
| ISSN: | 2165-6509 1092-8529 |
| Popis: | BackgroundMajor depressive disorder (MDD) and alcohol use disorder (AUD) are highly comorbid, with greater clinical complexity and psychosocial impairment. Several antidepressants have been used in this population, with mixed results. This preliminary study aims to investigate the effects of the multimodal antidepressant vortioxetine in MDD + AUD subjects.MethodsWe retrospectively evaluated 57 MDD + AUD and 56 MDD outpatients, matched for baseline characteristics. Patients were assessed after 1, 3, and 6 months treatment with vortioxetine (10-20 mg/d, flexibly dosed) in combination with continuous psychosocial support. The primary outcome was improvement in depressive symptoms measured by the Montgomery-Åsberg Depression Rating Scale. We also investigated changes in anxiety, anhedonia, cognition, functioning, quality of life, and clinical global severity using the following instruments: Hamilton Anxiety Rating Scale, Snaith-Hamilton Pleasure Scale, Digit Symbol Substitution Test, Perceived Deficits Questionnaire-Depression, Functioning Assessment Short Test, Quality of Life Index, and Clinical Global Impression-Severity Scale.ResultsVortioxetine significantly improved mood in MDD + AUD patients (P P = .36). A substantial rate (45.6%) of comorbid subjects obtained clinical remission at endpoint (P = .36 vs MDD). We additionally observed baseline to endpoint improvements on all secondary outcomes (P ConclusionsGiven its effectiveness on mood, cognition, and functioning, its good safety and tolerability profile, and low potential for abuse, vortioxetine could represent a valid pharmacological intervention in MDD + AUD patients as part of an integrated therapeutic-rehabilitation program. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|